Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/94690
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Falchook, G. | - |
dc.contributor.author | Long, G. | - |
dc.contributor.author | Kurzrock, R. | - |
dc.contributor.author | Kim, K. | - |
dc.contributor.author | Arkenau, H. | - |
dc.contributor.author | Brown, M. | - |
dc.contributor.author | Hamid, O. | - |
dc.contributor.author | Infante, J. | - |
dc.contributor.author | Millward, M. | - |
dc.contributor.author | Pavlick, A. | - |
dc.contributor.author | Chin, M. | - |
dc.contributor.author | O'Day, S. | - |
dc.contributor.author | Blackman, S. | - |
dc.contributor.author | Curtis, C. | - |
dc.contributor.author | Lebowitz, P. | - |
dc.contributor.author | Ma, B. | - |
dc.contributor.author | Ouellet, D. | - |
dc.contributor.author | Kefford, R. | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Clinical Cancer Research, 2014; 20(17):4449-4458 | - |
dc.identifier.issn | 1557-3265 | - |
dc.identifier.issn | 1557-3265 | - |
dc.identifier.uri | http://hdl.handle.net/2440/94690 | - |
dc.description.abstract | Abstract not available | - |
dc.description.statementofresponsibility | Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, H.-Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna Pavlick, Melvin T. Chin, Steven J. O'Day, Samuel C. Blackman, C. Martin Curtis, Peter Lebowitz, Bo Ma, Daniele Ouellet, and Richard F. Kefford | - |
dc.language.iso | en | - |
dc.publisher | American Association for Cancer Research | - |
dc.rights | © 2014 American Association for Cancer Research. | - |
dc.source.uri | http://dx.doi.org/10.1158/1078-0432.ccr-14-0887 | - |
dc.subject | Humans | - |
dc.subject | Melanoma | - |
dc.subject | Oximes | - |
dc.subject | Imidazoles | - |
dc.subject | Proto-Oncogene Proteins B-raf | - |
dc.subject | Protein Kinase Inhibitors | - |
dc.subject | Positron-Emission Tomography | - |
dc.subject | Treatment Outcome | - |
dc.subject | Drug Administration Schedule | - |
dc.subject | Dose-Response Relationship, Drug | - |
dc.subject | Mutation | - |
dc.subject | Adult | - |
dc.subject | Aged | - |
dc.subject | Aged, 80 and over | - |
dc.subject | Middle Aged | - |
dc.subject | Female | - |
dc.subject | Male | - |
dc.title | Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436) | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-14-0887 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Brown, M. [0000-0002-5796-1932] [0000-0002-6678-1407] | - |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.